• Palo Alto Investors LP opened a new position in Compass Therapeutics in the fourth quarter of 2025, acquiring 2,532,419 shares valued at about US$13.6 million, or roughly 1.89% of its assets under management.
• This move, alongside expectations for Compass’s bispecific antibody Tovecimig (CTX-009) in biliary tract cancer, highlights growing institutional interest in its oncology pipeline.
• Next, we will examine how rising institutional ownership, anchored by Palo Alto Investors’ new stake, reshapes Compass Therapeutics’ investment narrative.

This technology could replace computers: discover 22 stocks that are working to make quantum computing a reality.

What Is Compass Therapeutics' Investment Narrative?

For Compass Therapeutics, you really have to buy into the idea that its bispecific and antibody-based oncology programs can justify years of losses before any commercial payoff. The company has no revenue, is expected to remain unprofitable, and continues to tap equity markets, so dilution and funding risk sit front and center. That makes near term clinical and regulatory milestones for Tovecimig in biliary tract cancer, along with broader pipeline readouts, the key share price catalysts. Palo Alto Investors’ new US$13.6 million stake does not change these fundamentals, but it does reinforce that some institutions are willing to underwrite the clinical story despite the recent share price pullback. It may also support future capital raises if Compass seeks to extend its cash runway.

However, one risk around future funding and shareholder dilution is easy to overlook. Despite retreating, Compass Therapeutics' shares might still be trading above their fair value and there could be some more downside. Discover how much.

Exploring Other Perspectives

Two fair value estimates from the Simply Wall St Community span roughly US$13.57 to US$41.27 per share, showing how far opinions can stretch. Set against Compass’s ongoing losses and reliance on fresh capital, this spread underlines why you may want to weigh several viewpoints before deciding how its clinical and financing risks could influence long term outcomes.

Explore 2 other fair value estimates on Compass Therapeutics - why the stock might be worth just $13.57!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Compass Therapeutics research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Compass Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Compass Therapeutics' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• AI is about to change healthcare. These 28 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Uncover the next big thing with 30 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.